EMILIO
BOUZA SANTIAGO
Investigador hasta 2020
GlaxoSmithKline (United Kingdom)
Londres, Reino UnidoPublicaciones en colaboración con investigadores/as de GlaxoSmithKline (United Kingdom) (4)
2003
-
Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults
Journal of Antimicrobial Chemotherapy, Vol. 52, Núm. 5, pp. 826-836
2000
-
Streptococcus pneumoniae in community-acquired respiratory tract infections in Spain: The impact of serotype and geographical, seasonal and clinical factors on its susceptibility to the most commonly prescribed antibiotics
Journal of Antimicrobial Chemotherapy, Vol. 46, Núm. 4, pp. 557-564
1999
-
Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: Results of a 1-year (1996-1997) multicenter surveillance study
Antimicrobial Agents and Chemotherapy, Vol. 43, Núm. 2, pp. 357-359
-
Antimicrobial resistance of 914 beta-hemolytic streptococci isolated from pharyngeal swabs in Spain: Results of a 1-year (1996-1997) multicenter surveillance study
Antimicrobial Agents and Chemotherapy, Vol. 43, Núm. 1, pp. 178-180